CA3250172A1 - PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS - Google Patents
PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND ASSOCIATED PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- CA3250172A1 CA3250172A1 CA3250172A CA3250172A CA3250172A1 CA 3250172 A1 CA3250172 A1 CA 3250172A1 CA 3250172 A CA3250172 A CA 3250172A CA 3250172 A CA3250172 A CA 3250172A CA 3250172 A1 CA3250172 A1 CA 3250172A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amount
- compound
- formula
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305631P | 2022-02-01 | 2022-02-01 | |
| US63/305,631 | 2022-02-01 | ||
| PCT/US2023/061651 WO2023150500A1 (en) | 2022-02-01 | 2023-01-31 | Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3250172A1 true CA3250172A1 (en) | 2023-08-10 |
Family
ID=85556753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3250172A Pending CA3250172A1 (en) | 2022-02-01 | 2023-01-31 | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4472999A1 (https=) |
| JP (1) | JP2025506374A (https=) |
| KR (1) | KR20240137102A (https=) |
| CN (1) | CN118829647A (https=) |
| AU (1) | AU2023215245A1 (https=) |
| CA (1) | CA3250172A1 (https=) |
| CL (1) | CL2024002263A1 (https=) |
| IL (1) | IL314629A (https=) |
| MX (1) | MX2024009477A (https=) |
| PE (1) | PE20241895A1 (https=) |
| TW (1) | TW202342496A (https=) |
| UY (1) | UY40135A (https=) |
| WO (1) | WO2023150500A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322423A (en) | 2023-01-31 | 2025-09-01 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor |
| WO2025062347A1 (en) * | 2023-09-21 | 2025-03-27 | Janssen Pharmaceutica Nv | Interleukin-23 receptor antagonist for use in the treatment of ulcerative colitis |
| WO2025151385A1 (en) * | 2024-01-08 | 2025-07-17 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor and uses thereof |
| WO2025163534A1 (en) * | 2024-01-31 | 2025-08-07 | Janssen Pharmaceutica Nv | Crystal form of a peptide inhibitor of interleukin-23 receptor |
| WO2025243217A1 (en) * | 2024-05-22 | 2025-11-27 | Janssen Pharmaceutica Nv | Crystal forms of peptide molecules |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
-
2023
- 2023-01-31 IL IL314629A patent/IL314629A/en unknown
- 2023-01-31 TW TW112103335A patent/TW202342496A/zh unknown
- 2023-01-31 JP JP2024545861A patent/JP2025506374A/ja active Pending
- 2023-01-31 PE PE2024001727A patent/PE20241895A1/es unknown
- 2023-01-31 KR KR1020247029181A patent/KR20240137102A/ko active Pending
- 2023-01-31 CA CA3250172A patent/CA3250172A1/en active Pending
- 2023-01-31 CN CN202380019940.2A patent/CN118829647A/zh active Pending
- 2023-01-31 EP EP23710146.4A patent/EP4472999A1/en active Pending
- 2023-01-31 WO PCT/US2023/061651 patent/WO2023150500A1/en not_active Ceased
- 2023-01-31 AU AU2023215245A patent/AU2023215245A1/en active Pending
- 2023-02-01 UY UY0001040135A patent/UY40135A/es unknown
-
2024
- 2024-07-26 CL CL2024002263A patent/CL2024002263A1/es unknown
- 2024-07-31 MX MX2024009477A patent/MX2024009477A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342496A (zh) | 2023-11-01 |
| UY40135A (es) | 2023-08-31 |
| IL314629A (en) | 2024-09-01 |
| CN118829647A (zh) | 2024-10-22 |
| EP4472999A1 (en) | 2024-12-11 |
| KR20240137102A (ko) | 2024-09-19 |
| CL2024002263A1 (es) | 2025-02-07 |
| MX2024009477A (es) | 2024-11-08 |
| PE20241895A1 (es) | 2024-09-19 |
| WO2023150500A1 (en) | 2023-08-10 |
| JP2025506374A (ja) | 2025-03-11 |
| AU2023215245A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11939361B2 (en) | Compositions of peptide inhibitors of Interleukin-23 receptor | |
| CA3250172A1 (en) | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS | |
| AU763309B2 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
| CN103025317B (zh) | 钠布啡类制剂及其用途 | |
| CN103702664B (zh) | 通过两相控释系统的含普瑞巴林的缓释片 | |
| KR101317592B1 (ko) | 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제 | |
| CN105163735B (zh) | 用于治疗神经退行性疾病和其他疾病的组合物和方法 | |
| JP5778184B2 (ja) | 上皮増殖因子の経口投与可能薬学的ペレット | |
| JP2023145581A (ja) | インターロイキン－２３受容体のペプチド阻害剤の組成物 | |
| HK40117634A (zh) | 白介素-23受体的肽抑制剂及其药物组合物 | |
| IL322423A (en) | Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor | |
| EA051796B1 (ru) | Композиции пептидных ингибиторов рецептора интерлейкина-23 | |
| HK40092077A (zh) | 白介素-23受体的肽抑制剂的组合物 | |
| CN102088961A (zh) | 依普罗沙坦组合物 | |
| WO2025163534A1 (en) | Crystal form of a peptide inhibitor of interleukin-23 receptor | |
| TWI921644B (zh) | 固定劑量調配物 | |
| JP5044572B2 (ja) | イミダゾリルアルキル−ピリジンの安定な投薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240729 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250109 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250109 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250117 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250117 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250121 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250214 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260423 |